AbbVie and Genmab secured a first-line diffuse large B-cell lymphoma headline with Epkinly, reporting a Phase 3 win in newly diagnosed patients when added to R-CHOP. The companies said the therapy cut the risk of disease progression or death by nearly half versus R-CHOP alone, setting up a potential competitive head-to-head against Roche’s Polivy. Epkinly, a T-cell engager bispecific antibody, is already approved in the third-line setting in the U.S. under accelerated approval. The new data came from a trial enrolling about 900 patients at intermediate or high risk of death, and the companies framed the result as clearing a path toward a standard approval in first-line DLBCL. The report comes amid continued industry pressure to move immunotherapy earlier in disease, alongside attention to how bispecifics can be delivered beyond academic centers using remote monitoring approaches.